Lipolysis of LDL by human secretory phospholipase A2 induces particle fusion and enhances the retention of LDL to human aortic proteoglycans

被引:106
作者
Hakala, JK
Öörni, K
Pentikäinen, MO
Hurt-Camejo, E
Kovanen, PT
机构
[1] Wihuri Res Inst, FIN-00140 Helsinki, Finland
[2] Univ Gothenburg, Sahlgrens Univ Hosp, Dept Heart & Lung Dis, Wallenberg Lab Cardiovasc Res, Gothenburg, Sweden
[3] AstraZeneca, R&D, Cell Biol & Biochem, Molndal, Sweden
关键词
phospholipases; LDL; fusion; retention; proteoglycans;
D O I
10.1161/01.ATV.21.6.1053
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The first morphological sign of atherogenesis is the accumulation of extracellular lipid droplets in the proteoglycan-rich subendothelial layer of the arterial intima. Secretory nonpancreatic phospholipase A(2) (snpPLA(2)), an enzyme capable of lipolyzing LDL particles, is found in the arterial extracellular matrix and in contact with the extracellular lipid droplets. We have recently shown that in the presence of heparin, lipolysis of LDL with bee venom PLA(2) induces aggregation and fusion of the particles. Here, we studied the effect of human snpPLA(2) on the integrity of LDL particles and on their interaction with human aortic proteoglycans. In addition, the capacity of the proteoglycans to retain PLA(2)-lipolyzed LDL particles was tested in a microtiter well assay. We found that lipolysis of LDL induced fusion of proteoglycan-bound LDL particles, which increased their binding strength to the proteoglycans, Moreover, lipolysis of LDL with snpPLA(2) under physiological salt and albumin concentrations induced a 3-fold increase in the amount of LDL bound to proteoglycans. The results imply a role for PLA(2), in the retention and accumulation of LDL to the proteoglycan matrix in atherosclerosis.
引用
收藏
页码:1053 / 1058
页数:6
相关论文
共 48 条
[1]  
AGGERBECK LP, 1976, J BIOL CHEM, V251, P3823
[2]  
AMANUMA K, 1986, VIRCHOWS ARCH A, V410, P231
[3]   A MICRODETERMINATION METHOD FOR ASSAYING GLYCOSAMINOGLYCANS AND PROTEOGLYCANS [J].
BARTOLD, PM ;
PAGE, RC .
ANALYTICAL BIOCHEMISTRY, 1985, 150 (02) :320-324
[4]  
BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911
[5]   LABELING OF PROTEINS TO HIGH SPECIFIC RADIOACTIVITIES BY CONJUGATION TO A I-125-CONTAINING ACYLATING AGENT - APPLICATION TO RADIOIMMUNOASSAY [J].
BOLTON, AE ;
HUNTER, WM .
BIOCHEMICAL JOURNAL, 1973, 133 (03) :529-538
[6]   MODIFICATIONS OF LOW-DENSITY-LIPOPROTEIN INDUCED BY ARTERIAL PROTEOGLYCANS AND CHONDROITIN-6-SULFATE [J].
CAMEJO, G ;
HURT, E ;
WIKLUND, O ;
ROSENGREN, B ;
LOPEZ, F ;
BONDJERS, G .
BIOCHIMICA ET BIOPHYSICA ACTA, 1991, 1096 (03) :253-261
[7]   PARTIAL STRUCTURE OF THE ACTIVE MOIETY OF A LIPOPROTEIN COMPLEXING PROTEOGLYCAN FROM HUMAN AORTA [J].
CAMEJO, G ;
PONCE, E ;
LOPEZ, F ;
STAROSTA, R ;
HURT, E ;
ROMANO, M .
ATHEROSCLEROSIS, 1983, 49 (03) :241-254
[8]  
CHAO FF, 1990, AM J PATHOL, V136, P169
[9]  
Forte T, 1972, Adv Lipid Res, V10, P1
[10]  
FRANK JS, 1989, J LIPID RES, V30, P967